ProMIS Neurosciences shares are trading higher. The company announced blinded six-month interim safety and biomarker results for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s disease trial.

Benzinga Newsdesk www.benzinga.com Positive 84.2%

Neg 0% Neu 0% Pos 84.2%

Comments

No comments yet. Be the first!